B of A Securities Initiates Coverage On Sutro Biopharma with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has initiated coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and set a price target of $12.
May 08, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities initiated coverage on Sutro Biopharma with a Buy rating and a price target of $12.
The initiation of coverage by B of A Securities with a Buy rating and a price target of $12 is a strong positive signal for Sutro Biopharma. This endorsement from a reputable financial institution could lead to increased investor confidence and demand for STRO shares, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100